CuraGen and TopoTarget Start Leukemia Treatment Trial
Posted on: Wednesday, 29 August 2007, 15:12 CDT
CuraGen and TopoTarget have begun patient dosing in a Phase I/II clinical trial evaluating belinostat in combination with idarubicin for the treatment of acute myeloid leukemia.
The trial is being conducted at multiple sites in the European Union.
Patients under the age of 60 with relapsed or refractory acute myeloid leukemia (AML), or patients over 60 with newly diagnosed or previously treated AML, are eligible for enrollment in the trial.
Initially, 24 to 40 patients will be enrolled into one of two treatment arms and receive intravenous treatment with a combination of belinostat and idarubicin, an anthracycline. Patients will receive standard doses of idarubicin in combination with either belinostat administered intravenously once daily for five days, or a continuous infusion of belinostat over 24 to 48 hours.
Enrollment into the arms will occur in parallel in order to assess safety and define the maximum tolerated dose (MTD) for each treatment regimen. Upon establishing the MTD for each treatment arm, the trial will be advanced into Phase II to further define the safety and efficacy of belinostat in combination with standard doses of idarubicin.
Patients demonstrating complete or partial response will continue to receive treatment with belinostat until disease progression. The primary objectives for the study include safety, tolerability, and efficacy for each treatment regimen. Secondary objectives include time to response, duration of response, and survival.
The trial will also include pharmacokinetic and pharmacodynamic studies to evaluate the inhibition of histone deacetylase (HDAC) enzymes in AML cells from patients treated with belinostat. Evaluation of the genes regulating proliferation and apoptosis (programmed cell death) and the differential gene expression in AML cells obtained both prior to and following treatment with belinostat will also be performed.
In preclinical studies, belinostat has shown potent growth-inhibitory activity on leukemic cell lines, and there is evidence that belinostat has an additive effect when combined with anthracyclines, according to the companies.
Source: Datamonitor
Related Articles
- Javelin Enrolls First Patient in an Open Label Safety Study of Dyloject(TM)
- Sciele Completes Enrollment of Patients in Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Sciele Begins to Enroll Patients in a Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
- Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML
- Cytogen Announces Positive Interim Findings From a Phase I Clinical Trial of QUADRAMET(R) Combination Study in Patients With Relapsed Multiple Myeloma
- Callisto Announces Appointment of Dr. Arthur Sytkowski As Clinical Trial Advisor and Medical Safety Monitor
- Xanthus Initiates a Phase 2 Study Of Xanafide in Combination With Ara-C for Treatment Of Secondary AML
- StaphVAX(R) Immunogenicity Study in Cardiac Patients Meets Primary Endpoints of Safety and Immune Response
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
 |
 |
User Comments (0)
RSS Feeds